|
1
|
Eddy AA and Symons JM: Nephrotic syndrome
in childhood. Lancet. 362:629–639. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shi XM, Liu BN, Zhong XH, Wang F and Ding
J: Epidemiology of chronic kidney disease in children. Zhonghua Er
Ke Za Zhi. 57:721–724. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
3
|
United States Renal Data System: 2018
USRDS annual data report: ESRD among children, adolescents, and
young adults (EB/OL) 2018.
|
|
4
|
Aggarwal A, Yadav AK, Ramachandran R,
Kumar V, Kumar V, Sachdeva N, Khandelwal N and Jha V: Bioavailable
vitamin D levels are reduced and correlate with bone mineral
density and markers of mineral metabolism in adults with nephrotic
syndrome. Nephrology (Carlton). 21:483–489. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Takashi Y and Fukumoto S: FGF23 beyond
phosphotropic hormone. Trends Endocrinol Metab. 29:755–767.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kurosu H and Kuro-O M: The Klotho gene
family as a regulator of endocrine fibroblast growth factors. Mol
Cell Endocrinol. 299:72–78. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Edmonston D and Wolf M: FGF23 at the
crossroads of phosphate, iron economy and erythropoiesis. Nat Rev
Nephrol. 16:7–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Perwad F, Zhang MY, Tenenhouse HS and
Portale AA: Fibroblast growth factor 23 impairs phosphorus and
vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin
D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal
Physiol. 293:F1577–F1583. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Meir T, Durlacher K, Pan Z, Amir G,
Richards WG, Silver J and Naveh-Many T: Parathyroid hormone
activates the orphan nuclear receptor Nurr1 to induce FGF23
transcription. Kidney Int. 86:1106–1115. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bai X, Miao D, Li J, Goltzman D and
Karaplis AC: Transgenic mice overexpressing human fibroblast growth
factor 23 (R176Q) delineate a putative role for parathyroid hormone
in renal phosphate wasting disorders. Endocrinology. 145:5269–5279.
2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Razzaque MS and Lanske B: The emerging
role of the fibroblast growth factor-23-klotho axis in renal
regulation of phosphate homeostasis. J Endocrinol. 194:1–10.
2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu S and Quarles LD: How fibroblast
growth factor 23 works. J Am Soc Nephrol. 18:1637–1647.
2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gutierrez O, Isakova T, Rhee E, Shah A,
Holmes J, Collerone G, Jüppner H and Wolf M: Fibroblast growth
factor-23 mitigates hyperphosphatemia but accentuates calcitriol
deficiency in chronic kidney disease. J Am Soc Nephrol.
16:2205–2215. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stubbs J, Liu S and Quarles LD: Role of
fibroblast growth factor 23 in phosphate homeostasis and
pathogenesis of disordered mineral metabolism in chronic kidney
disease. J Semin Dial. 20:302–308. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Park SY, Jeong KH, Moon JY, Lee SH, Ihm
CG, Rhee SY, Woo JT, Oh IH and Lee TW: The relationship between
circulating fibroblast growth factor 23 and bone metabolism factors
in Korean hemodialysis patients. Clin Exp Nephrol. 14:239–243.
2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Figge J, Jabor A, Kazda A and Fencl V:
Anion gap and hypoalbuminemia. Crit Care Med. 26:1807–1810.
1998.PubMed/NCBI View Article : Google Scholar
|
|
17
|
van Husen M, Fischer AK, Lehnhardt A,
Klaassen I, Möller K, Müller-Wiefel DE and Kemper MJ: Fibroblast
growth factor 23 and bone metabolism in children with chronic
kidney disease. Kidney Int. 78:200–206. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bacchetta J, Dubourg L, Harambat J,
Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M and
Cochat P: The influence of glomerular filtration rate and age on
fibroblast growth factor 23 serum levels in pediatric chronic
kidney disease. J Clin Endocrinol Metab. 95:1741–1748.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
de Seigneux S, Courbebaisse M, Rutkowski
JM, Wilhelm-Bals A, Metzger M, Khodo SN, Hasler U, Chehade H, Dizin
E, Daryadel A, et al: Proteinuria increases plasma phosphate by
altering its tubular handling. J Am Soc Nephrol. 26:1608–1618.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yadav AK, Ramachandran R, Aggarwal A,
Kumar V, Gupta KL and Jha V: Fibroblast growth factor 23 in
untreated nephrotic syndrome. Nephrology (Carlton). 23:362–365.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Isakova T, Xie H, Yang W, Xie D, Anderson
AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, et al:
Fibroblast growth factor 23 and risks of mortality and end-stage
renal disease in patients with chronic kidney disease. JAMA.
305:2432–2439. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Trautvetter U, Jahreis G, Kiehntopf M and
Glei M: Consequences of a high phosphorus intake on mineral
metabolism and bone remodeling in dependence of calcium intake in
healthy subjects-a randomized placebo-controlled human intervention
study. Nutr J. 15:1–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Siomou E, Challa A, Printza N, Giapros V,
Petropoulou F, Mitsioni A, Papachristou F and Stefanidis CJ: Serum
osteoprotegerin, RANKL and fibroblast growth factor-23 in children
with chronic kidney disease. Pediatr Nephrol. 26:1105–1114.
2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wesseling-Perry K, Tsai EW, Ettenger RB,
Jüppner H and Salusky IB: Mineral abnormalities and long-term graft
function in pediatric renal transplant recipients: A role for
FGF-23. Nephrol Dial Transplant. 26:3779–3784. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shimada T, Yamazaki Y, Takahashi M,
Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K,
Fujita T, et al: Vitamin D receptor-independent FGF23 actions in
regulating phosphate and vitamin D metabolism. Am J Physiol Renal
Physiol. 289:F1088–F1095. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cancela AL, Oliveira RB, Graciolli FG, dos
Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB,
Canziani ME, et al: Fibroblast growth factor 23 in hemodialysis
patients: effects of phosphate binder, calcitriol and calcium
concentration in the dialysate. Nephron Clin Pract. 117:c74–c82.
2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lanske B and Razzaque MS: Molecular
interactions of FGF23 and PTH in phosphate regulation. Kidney Int.
86:1072–1074. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Galitzer H, Ben-Dov IZ, Silver J and
Naveh-Many T: Parathyroid cell resistance to fibroblast growth
factor 23 in secondary hyperparathyroidism of chronic kidney
disease. Kidney Int. 77:211–218. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pavik I, Jaeger P, Ebner L, Wagner CA,
Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S and Serra
AL: Secreted Klotho and FGF23 in chronic kidney disease stage 1 to
5: A sequence suggested from a cross-sectional study. Nephrol Dial
Transplant. 28:352–359. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sato KA, Gray RW and Lemann J: Urinary
excretion of 25-hydroxyvitamin D in health and the nephrotic
syndrome. J Lab Clin Med. 99:325–330. 1982.PubMed/NCBI
|
